Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin - 1-year results of a randomized clinical trial - VIP report no. 1

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Ophthalmology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0161-6420(01)00544-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

  2001cited by this paper
• A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

  2000cited by this paper
• Subfoveal neovascular lesions in age-related macular degeneration.

  1993cited by this paper
• [Subretinal neovessels in degenerative myopia: results of photocoagulation].

  1986cited by this paper
• Pathologic myopia and choroidal neovascularization.

  1981cited by this paper
• Natural History of Fuchs’ Spot: A Long-Term Follow-Up Study

  1981cited by this paper

• Long-Term retrospective analysis of retinal pigment epithelium atrophy and secondary hyperplasia following verteporfin photodynamic therapy.

  2025cites this paper
• Real-world data of verteporfin-related ocular adverse events: A disproportionality analysis.

  2025cites this paper
• Photodynamic treatment without verteporfin in chronic central serous chorioretinopathy

  2025cites this paper
• Frontiers of myopia research in the 21st century: A bibliometric analysis of the top 100 most influential articles in the field

  2024cites this paper
• Recent Advances in Photodynamic Therapy for Vascular Abnormalities

  2024cites this paper
• Myopie forte

  2024cites this paper
• Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study

  2023cites this paper
• Safety and Efficacy of Photodynamic Therapy in the Treatment of Circumscribed Choroidal Hemangioma: A Systematic Review

  2023cites this paper
• Treatment of myopic choroidal neovascularization: a network meta-analysis and review

  2023cites this paper
• Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients

  2022cites this paper
• Myopia: A Historical Perspective

  2021cites this paper
• Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients

  2021cites this paper
• Choroidal Neovascularization

  2020cites this paper
• Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN).

  2019influential citation
• Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12‐month results from a randomized controlled study

  2018cites this paper
• Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

  2018cites this paper
• Drug Delivery for the Retina and Posterior Segment Disease

  2018cites this paper
• Lamellar macular holes in the eyes with pathological myopia

  2018cites this paper
• Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.

  2017cites this paper
• CLINICAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB VERSUS PHOTODYNAMIC THERAPY WITH OR WITHOUT BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION: A 7-Year Follow-up Study

  2017cites this paper
• Inhibition of Laser-Induced Choroidal Neovascularization by Hematoporphyrin Dimethylether-Mediated Photodynamic Therapy in Rats.

  2017cites this paper
• Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study

  2017cites this paper
• Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia

  2017cites this paper
• Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis

  2017cites this paper
• Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia

  2017cites this paper
• Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes

  2016cites this paper
• Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia

  2016cites this paper
• Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application

  2015cites this paper
• Current and emerging treatment options for myopic choroidal neovascularization

  2015cites this paper
• CLINICAL INVESTIGATION : Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab

  2015cites this paper
• Ophthalmic pharmaceutical clinical trials: design considerations

  2015cites this paper
• Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis

  2014cites this paper
• 25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina

  2014cites this paper
• Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab

  2014cites this paper
• Myopic choroidal neovascularisation: current concepts and update on clinical management

  2014cites this paper
• RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.

  2014cites this paper
• [Evaluation of antiangiogenic treatment results in choroidal neovascularization related to pathological myopia].

  2014cites this paper
• Two-Year Outcome of Intravitreal Injections of Ranibizumab for Myopic Choroidal Neovascularization

  2014cites this paper
• Progress of anti‐vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges

  2014cites this paper
• Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

  2014cites this paper
• Photodynamic therapy for polypoidal choroidal vasculopathy.

  2013cites this paper
• [Intravitreal bevacizumab injections versus verteporferin photodynamic therapy for macular choroidal neovascularization in high myopia: 24-month follow-up].

  2013cites this paper
• Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

  2013cites this paper
• Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.

  2013cites this paper
• Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy

  2013cites this paper
• Choroidal neovascularization following laser in situ keratomileusis for high myopia: a case series

  2013cites this paper
• Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors

  2012cites this paper
• Evaluation of verteporfin pharmakokinetics – redefining the need of photosensitizers in ophthalmology

  2012cites this paper
• Myopic Maculopathy: A Review

  2012cites this paper
• Choroidal neovascularization in pathological myopia.

  2012cites this paper
• The 12-Month Outcome of Three Consecutive Monthly Intravitreal Injections of Ranibizumab for Myopic Choroidal Neovascularization

  2012cites this paper
• Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.

  2012cites this paper
• Intravitreal Bevacizumab for a Subfoveal Myopic Choroidal Neovascularization in the First Trimester of Pregnancy

  2012cites this paper
• Verteporfin

  2012cites this paper
• Myope CNV

  2011cites this paper
• Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab

  2011cites this paper
• Intravitreal Injection of 2.5 mg Bevacizumab for Treatment of Myopic Choroidal Neovascularization in Treatment-Naive Cases: A 2-Year Follow-Up

  2011cites this paper
• Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations.

  2011cites this paper
• Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population

  2011cites this paper
• Characteristics of periconus choroidal neovascularization in pathologic myopia.

  2011cites this paper
• ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY VERSUS COMBINATION TREATMENT WITH PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO CAUSES OTHER THAN AGE-RELATED MACULAR DEGENERATION

  2011cites this paper
• Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment.

  2011cites this paper
• Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses

  2011cites this paper
• Neuroprotective response after photodynamic therapy: Role of vascular endothelial growth factor

  2011cites this paper
• Genetic Predictors of Response to Photodynamic Therapy

  2011cites this paper
• Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

  2011cites this paper
• Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.

  2010cites this paper
• Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

  2010cites this paper
• Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety

  2010cites this paper
• Long-term control of choroidal neovascularization in quiescent congenital toxoplasma retinochoroiditis with photodynamic therapy: 4-year results

  2010cites this paper
• The effect of laser unit on photodynamic therapy spot size

  2010cites this paper
• Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

  2010cites this paper
• [Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD)].

  2009cites this paper
• Glare testing in patients with cataract after dilation.

  2009cites this paper
• Bevacizumab (Avastin) for the treatment of ocular disease.

  2009cites this paper
• Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy

  2009cites this paper
• Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

  2009cites this paper
• Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

  2009cites this paper
• Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan

  2009cites this paper
• Small tarsal plates causing recurrent lower lid entropion in a young adult

  2009cites this paper
• Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

  2009cites this paper
• Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, Japan

  2009cites this paper
• Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results

  2009cites this paper
• Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.

  2009cites this paper
• A Masking Device and Method to Create Custom Laser Exposure Patterns for Verteporfin Photodynamic Therapy

  2008cites this paper
• Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.

  2008cites this paper
• Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy

  2008cites this paper
• Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years’ outcome

  2008cites this paper
• Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis

  2008cites this paper
• Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

  2008cites this paper
• Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas

  2008cites this paper
• Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.

  2008cites this paper
• Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

  2008cites this paper
• Indikationen für photodynamische Therapie mit Verteporfin im Zeitalter der intravitrealen Therapie – eine Übersicht

  2008cites this paper
• Avastin in myopic choroidal neovascularisation: is age the limit?

  2008cites this paper
• Photodynamic therapy for corneal neovascularization using polymeric micelles encapsulating dendrimer porphyrins.

  2008cites this paper
• Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

  2008cites this paper
• Intravitreal Bevacizumab (Avastin) as Primary Treatment for Myopic Choroidal Neovascularization

  2007cites this paper
• Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization.

  2007cites this paper
• Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

  2007cites this paper